195 related articles for article (PubMed ID: 16361559)
1. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
3. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
6. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
7. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
8. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
9. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
10. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
[TBL] [Abstract][Full Text] [Related]
11. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
[TBL] [Abstract][Full Text] [Related]
12. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
13. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
14. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA; Poggesi I; Robson M; Asnis A; Duncan BA; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler MN
Breast Cancer Res Treat; 2008 Sep; 111(2):377-88. PubMed ID: 17952589
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
18. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Bahrami N; Chang G; Kanaya N; Sauer T; Park D; Loeng M; Gravdehaug B; Chen S; Geisler J
J Steroid Biochem Mol Biol; 2020 Jun; 200():105641. PubMed ID: 32151708
[TBL] [Abstract][Full Text] [Related]
20. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
[Next] [New Search]
